Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Thursday, March 28, 2024 · 699,554,309 Articles · 3+ Million Readers

Global Vaccine Partnering Terms and Agreements Directory 2010-2018

Dublin, May 22, 2018 (GLOBE NEWSWIRE) -- The "Global Vaccine Partnering Terms and Agreements 2010-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

The Global Vaccine Partnering Terms and Agreements 2010-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

One of the key highlights of the report is that over 1,000 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Global Vaccine Partnering Terms and Agreements 2010-2018

  • Trends in vaccine dealmaking in the biopharma industry since 2010
  • Analysis of vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life vaccine deals
  • Access to over 1,000 vaccine deal documents
  • The leading vaccine deals by value since 2010
  • Most active vaccine dealmakers since 2010
  • The leading vaccine partnering resources

Available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy target
  • Specific technology type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Vaccines dealmaking

2.1. Introduction
2.2. Vaccines partnering over the years
2.3. Most active Vaccines dealmakers
2.4. Vaccines partnering by deal type
2.5. Vaccines partnering by therapy area
2.6. Deal terms for Vaccines partnering
2.6.1 Vaccines partnering headline values
2.6.2 Vaccines deal upfront payments
2.6.3 Vaccines deal milestone payments
2.6.4 Vaccines royalty rates

Chapter 3 - Leading Vaccines deals

3.1. Introduction
3.2. Top Vaccines deals by value

Chapter 4 - Most active Vaccines dealmakers

4.1. Introduction
4.2. Most active Vaccines dealmakers
4.3. Most active Vaccines partnering company profiles

Chapter 5 - Vaccines contracts dealmaking directory

5.1. Introduction
5.2. Vaccines contracts dealmaking directory

Chapter 6 - Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Vaccines deals by company A-Z

Appendix 2 - Vaccines deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Vaccines deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

Appendix 4 - Vaccines deals by therapy area

Anaesthetics
Cardiovascular
Central Nervous System
Dental
Gastrointestinal
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Respiratory

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/gzrxqj/global_vaccine?w=12

                    
                    
                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Vaccines
                    

Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release